ArticleJournal of clinical microbiology2014
Head-to-head comparison of second-generation nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae on urine samples from female subjects and self-collected vaginal swabs.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Pooled it
- Vaginal Swab vs Urine for Detection ofAnnals of family medicinePooled it
- Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection.The New England journal of medicine · 2015Trial
- Surveillance forMicrobiology spectrum · 2025Article
- Advances in molecular infectious diseases testing in the time of COVID-19.Clinical biochemistry · 2023Review
- Mapping Evidence of Self-Sampling to Diagnose Sexually Transmitted Infections in Women: A Scoping Review.Diagnostics (Basel, Switzerland) · 2022Article
- Screening for chlamydia and gonorrhea in primary care in populations with low prevalence.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2021Article
- Chlamydia trachomatis in Iceland: Prevalence, Clinico-epidemiological Features and Comparison of Cobas 480 CT/NG and Aptima Combo 2 (CT/NG) for Diagnosis.Acta dermato-venereologica · 2021Article
- Despite Excellent Test Characteristics of the cobas 4800 CT/NG Assay, Detection of Oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae Remains Challenging.Journal of clinical microbiology · 2021Article
- Precision of the Abbott RealTime Assay in the Detection of OcularThe American journal of tropical medicine and hygiene · 2020Article
- Article
- The Finnish New Variant ofMicroorganisms · 2019Article
- Comparison between DiaPlexQ™ STI6 and GeneFinder™ STD I/STD II multiplex Real-time PCR Kits in the detection of six sexually transmitted disease pathogens.Journal of clinical laboratory analysis · 2019Article
- Implementation and evaluation of the Presto combined qualitative real-time assay forAfrican journal of laboratory medicine · 2019Article
- Diagnostic Molecular Microbiology: A 2018 Snapshot.Clinics in laboratory medicine · 2018Review
- Evaluation of the cobas Cdiff Test for Detection of Toxigenic Clostridium difficile in Stool Samples.Journal of clinical microbiology · 2017Article
- A recommendation for timing of repeat Chlamydia trachomatis test following infection and treatment in pregnant and nonpregnant women.International journal of STD & AIDS · 2017Article
- Detection ofThe Indian journal of medical research · 2017Article
- The new frontier of diagnostics: Molecular assays and their role in infection prevention and control.American journal of infection control · 2017Review
- Sample-to-result molecular infectious disease assays: clinical implications, limitations and potential.Expert review of molecular diagnostics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a comparison of 4 second-generation nucleic acid amplification tests performed with self-collected vaginal swab (SCVS) and first-void urine (FVU) specimens from 575 women, SCVS specimens indicated more infections than did FVU specimens in all assays. The prevalence rates were 9% (53/575 patients) for Chlamydia trachomatis and 2% (11/575 patients) for Neisseria gonorrhoeae. The clinical sensitivities for testing SCVS specimens for C. trachomatis were 98.1% on a Tigris system and 96.2% on a Panther system for the Aptima Combo 2 assay (Hologic Gen-Probe), 98.0% for the RealTime CT/NG assay on an m2000 instrument (Abbott), 90.6% for the ProbeTec CT/GC Q(x) assay on the Viper system (Becton Dickinson), and 84.6% for the cobas CT/NG assay on the cobas 4800 platform (Roche). Clinical sensitivities for C. trachomatis in FVU specimens were 88.7% (Tigris) and 88.0% (Panther) for the Aptima Combo 2 assay, 76.9% for the RealTime CT/NG assay, 75.5% for the ProbeTec CT/GC Q(x) assay, and 81.1% for the cobas CT/NG assay. Clinical sensitivities of the assays for N. gonorrhoeae, with limited positive results, ranged from 63.6% to 100%. Specificities for both infections ranged from 98.4 to 100%. Differences in analytical sensitivities and levels of molecular targets in clinical samples but not inhibitors of amplification may explain the differences in clinical sensitivities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.